SCHEMBL426543

SCHEMBL426543

CCOC(=O)c1cc(-c2cccc(Cl)c2)cs1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
ALOX5 P09917 4/20 0.47
MAPT P10636 3/20 0.47
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
PTGES O14684 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
JAK2 O60674 1/20 0.45
JAK3 P52333 1/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
RORC P51449 1/20 0.44
CHRNA7 P36544 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6880257 0.84 MMP12 (0.53) TRPM8MAPTKDM4EALDH1A1HPGD
SCHEMBL2483240 0.79 L3MBTL1 (0.46) TRPM8L3MBTL1ALOX5MAPTPDE4A
SCHEMBL1808654 0.79 MMP12 (0.53) TRPM8MAPTKDM4EALDH1A1HPGD
SCHEMBL8654477 0.78 PRKCZ (0.44) L3MBTL1MAPTALDH1A1
SCHEMBL7759940 0.77 TRPV1 (0.61) TRPM8ALOX5MAPTPTGESTRPV1
SCHEMBL10109873 0.76 TRPM8 (0.54) TRPM8L3MBTL1ALOX5MAPTPDE4A
SCHEMBL423837 0.75 TRPM8 (0.53) TRPM8L3MBTL1ALOX5MAPTPDE4A
SCHEMBL422050 0.75 TRPM8 (0.53) TRPM8L3MBTL1ALOX5MAPTPDE4A
SCHEMBL12942140 0.75 L3MBTL1 (0.61) TRPM8L3MBTL1ALOX5MAPTPDE4A
SCHEMBL18974750 0.75 NPC1 (0.68) TRPM8L3MBTL1ALOX5MAPTPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
EP-2376482-B1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2013-03-06 EP disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
WO-2010075962-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 TRPM8 3898/4885L3MBTL1 633/4885ALOX5 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.